Insider Selling: United Therapeutics Corp. EVP Sells 6,000 Shares of Stock (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) EVP Paul A. Mahon sold 6,000 shares of the stock on the open market in a transaction dated Thursday, January 16th. The shares were sold at an average price of $111.98, for a total value of $671,880.00. Following the sale, the executive vice president now directly owns 34,490 shares in the company, valued at approximately $3,862,190. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Argus raised their price target on shares of United Therapeutics Corp. from $120.00 to $130.00 in a research note to investors on Tuesday, December 31st. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Separately, analysts at Jefferies Group raised their price target on shares of United Therapeutics Corp. from $76.00 to $91.00 in a research note to investors on Tuesday, December 24th. They now have a “hold” rating on the stock. Finally, analysts at Ladenburg Thalmann upgraded shares of United Therapeutics Corp. from a “neutral” rating to a “buy” rating in a research note to investors on Monday, December 23rd. They now have a $138.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $88.21.
Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded down 0.74% during mid-day trading on Friday, hitting $112.48. 176,961 shares of the company’s stock traded hands. United Therapeutics Corp. has a 1-year low of $51.82 and a 1-year high of $116.65. The stock’s 50-day moving average is $101.0 and its 200-day moving average is $83.92. The company has a market cap of $5.649 billion and a P/E ratio of 20.59.
United Therapeutics Corp. (NASDAQ:UTHR) last announced its earnings results on Tuesday, October 29th. The company reported $2.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.59 by $1.39. The company had revenue of $302.20 million for the quarter, compared to the consensus estimate of $279.02 million. During the same quarter in the previous year, the company posted $2.82 earnings per share. The company’s revenue for the quarter was up 24.6% on a year-over-year basis. Analysts expect that United Therapeutics Corp. will post $5.42 EPS for the current fiscal year.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.